ETON Strangle Strategy
ETON (Eton Pharmaceuticals, Inc.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
ETON (Eton Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $977.9M, a beta of 0.89 versus the broader market, a 52-week range of 13.51-35.99, average daily share volume of 416K, a public-listing history dating back to 2018, approximately 44 full-time employees. These structural characteristics shape how ETON stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.89 places ETON roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on ETON?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current ETON snapshot
As of June 29, 2026, spot at $36.70, ATM IV 77.40%, IV rank 19.35%, expected move 22.19%. The strangle on ETON below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on ETON specifically: ETON IV at 77.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a ETON strangle, with a market-implied 1-standard-deviation move of approximately 22.19% (roughly $8.14 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ETON expiries trade a higher absolute premium for lower per-day decay. Position sizing on ETON should anchor to the underlying notional of $36.70 per share and to the trader's directional view on ETON stock.
ETON strangle setup
The ETON strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ETON near $36.70, the first option leg uses a $38.54 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ETON chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ETON shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $38.54 | N/A |
| Buy 1 | Put | $34.87 | N/A |
ETON strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
ETON strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on ETON. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on ETON
Strangles on ETON are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ETON chain.
ETON thesis for this strangle
The market-implied 1-standard-deviation range for ETON extends from approximately $28.56 on the downside to $44.84 on the upside. A ETON long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current ETON IV rank near 19.35% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ETON at 77.40%. As a Healthcare name, ETON options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ETON-specific events.
ETON strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ETON positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ETON alongside the broader basket even when ETON-specific fundamentals are unchanged. Always rebuild the position from current ETON chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on ETON?
- A strangle on ETON is the strangle strategy applied to ETON (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With ETON stock trading near $36.70, the strikes shown on this page are snapped to the nearest listed ETON chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ETON strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the ETON strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 77.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ETON strangle?
- The breakeven for the ETON strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ETON market-implied 1-standard-deviation expected move is approximately 22.19%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on ETON?
- Strangles on ETON are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the ETON chain.
- How does current ETON implied volatility affect this strangle?
- ETON ATM IV is at 77.40% with IV rank near 19.35%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.